Dynavax Technologies Corporation | Small-cap | Healthcare
$10.50
-4.11%
| Dynavax Technologies Stock Comparison:
Dynavax Technologies vs ZoetisDynavax Technologies vs Haleon Plc - ADRDynavax Technologies vs Ani PharmaceuticalsDynavax Technologies vs BioCrystDynavax Technologies vs BGMDynavax Technologies vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 95.4M
Gross Profit 81.4M 85.29%
Operating Income 14.4M 15.12%
Net Income 18.7M 19.62%
EPS (Diluted) $0.14

Balance Sheet Metrics

Total Assets 945.9M
Total Liabilities 415.0M
Shareholders Equity 530.9M
Debt to Equity 0.78

Cash Flow Metrics

Operating Cash Flow -101.7M
Free Cash Flow -23.6M

Revenue & Profitability Trend

Dynavax Technologies Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i277.2M232.3M722.7M439.4M46.6M
Cost of Goods Sold i49.4M50.2M262.2M173.6M13.9M
Gross Profit i227.8M182.1M460.5M265.9M32.6M
Gross Margin % i82.2%78.4%63.7%60.5%70.1%
Operating Expenses
Research & Development i61.6M54.9M46.6M32.2M28.6M
Selling, General & Administrative i170.4M152.9M131.4M100.2M79.3M
Other Operating Expenses i-----
Total Operating Expenses i231.9M207.8M178.0M132.4M107.9M
Operating Income i-4.1M-25.7M282.5M133.5M-75.2M
Operating Margin % i-1.5%-11.1%39.1%30.4%-161.6%
Non-Operating Items
Interest Income i36.5M32.0M7.9M140.0K1.3M
Interest Expense i6.8M6.8M6.7M11.2M19.1M
Other Non-Operating Income5.3M-3.9M10.6M-44.9M17.8M
Pre-tax Income i30.9M-4.4M294.3M77.5M-75.2M
Income Tax i3.5M2.0M1.1M808.0K0
Effective Tax Rate % i11.5%0.0%0.4%1.0%0.0%
Net Income i27.3M-6.4M293.2M76.7M-75.2M
Net Margin % i9.9%-2.8%40.6%17.5%-161.6%
Key Metrics
EBITDA i45.7M21.0M304.9M149.3M-57.8M
EPS (Basic) i$0.21$-0.05$2.32$0.62$-0.75
EPS (Diluted) i$0.20$-0.05$1.97$0.57$-0.78
Basic Shares Outstanding i130047000128733000126398000116264000100753000
Diluted Shares Outstanding i130047000128733000126398000116264000100753000

Income Statement Trend

Dynavax Technologies Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i95.9M150.3M202.0M436.2M32.1M
Short-term Investments i618.0M592.0M422.4M109.8M133.0M
Accounts Receivable i45.3M40.6M145.1M116.2M22.3M
Inventory i70.1M53.3M59.4M61.3M63.7M
Other Current Assets18.1M19.0M85.6M73.8M-
Total Current Assets i848.9M859.1M917.0M972.5M290.0M
Non-Current Assets
Property, Plant & Equipment i39.8M42.9M43.2M41.0M43.4M
Goodwill i3.9M4.1M4.0M4.2M4.6M
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets74.8M74.3M3.5M3.6M3.8M
Total Non-Current Assets i137.3M138.0M68.9M66.7M63.3M
Total Assets i986.3M997.1M985.8M1.0B353.3M
Liabilities
Current Liabilities
Accounts Payable i9.1M5.2M3.2M2.6M3.3M
Short-term Debt i4.2M4.5M3.6M2.6M3.2M
Current Portion of Long-term Debt-----
Other Current Liabilities22.0K24.0K-18.0M10.7M
Total Current Liabilities i78.6M62.2M150.1M556.4M77.4M
Non-Current Liabilities
Long-term Debt i250.2M252.4M254.4M254.8M214.6M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities244.0K74.0K384.0K5.7M2.6M
Total Non-Current Liabilities i310.8M312.8M254.8M260.5M217.2M
Total Liabilities i389.5M375.0M404.8M816.9M294.6M
Equity
Common Stock i125.0K130.0K128.0K123.0K110.0K
Retained Earnings i-903.3M-930.6M-924.2M-1.2B-1.3B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i596.8M622.1M581.0M222.4M58.7M
Key Metrics
Total Debt i254.4M256.9M258.0M257.4M217.8M
Working Capital i770.3M796.9M766.9M416.1M212.6M

Balance Sheet Composition

Dynavax Technologies Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i27.3M-6.4M293.2M76.7M-75.2M
Depreciation & Amortization i8.1M7.3M6.7M7.1M9.3M
Stock-Based Compensation i52.6M42.6M32.9M21.3M13.5M
Working Capital Changes i-24.0M46.1M-400.3M198.4M-4.5M
Operating Cash Flow i70.0M90.7M-66.5M305.1M-53.2M
Investing Activities
Capital Expenditures i-6.4M-4.1M-7.1M-9.5M-4.1M
Acquisitions i-----
Investment Purchases i-524.1M-636.9M-632.3M-164.9M-201.8M
Investment Sales i512.4M486.1M322.4M187.6M179.5M
Investing Cash Flow i-18.0M-154.9M-317.0M13.2M-26.4M
Financing Activities
Share Repurchases i-100.0M----
Dividends Paid i-----
Debt Issuance i-00219.8M0
Debt Repayment i-00-190.2M0
Financing Cash Flow i-109.3M-6.5M030.5M108.5M
Free Cash Flow i60.2M96.5M55.6M326.1M-103.3M
Net Change in Cash i-57.4M-70.8M-383.5M348.9M28.9M

Cash Flow Trend

Dynavax Technologies Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 54.60
Forward P/E 30.42
Price to Book 2.60
Price to Sales 4.06
PEG Ratio 0.70

Profitability Ratios

Profit Margin -16.67%
Operating Margin 17.45%
Return on Equity -9.28%
Return on Assets 0.52%

Financial Health

Current Ratio 6.65
Debt to Equity 58.60
Beta 1.09

Per Share Data

EPS (TTM) $-0.45
Book Value per Share $4.22
Revenue per Share $2.51

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
dvax1.3B54.602.60-9.28%-16.67%58.60
Zoetis 65.3B25.3613.1452.77%27.83%137.01
Haleon Plc - ADR 44.7B21.825.549.38%13.81%53.41
Ani Pharmaceuticals 2.0B51.634.19-2.17%-1.37%136.10
BioCryst 1.8B-19.94-4.2618.68%-6.41%-1.75
BGM 1.5B15.004.06-16.52%-26.32%0.22

Financial data is updated regularly. All figures are in the company's reporting currency.